Effects of plateletpheresis on blood coagulation parameters in healthy donors at National Blood Centre, Kuala Lumpur, Malaysia

Nadiah, A.K. Siti; Asiah, M. Nor; Syimah, A. T. Nur; Normi, M.; Anza, E.; Aini, A. Nor; Zahari, T. H. Mohd; Shahnaz, M; Faraizah, A.K.; Faisal, Mostafa

doi:10.1016/j.transci.2013.08.004

Cited by 16 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Burnouf et al (2003) in a study showed very low levels of complement products in various apheresis methods, which may be due to consumption of plasma proteins during apheresis method whereas, Bock et al (2002) showed the lower C3 degradation products in apheresis platelet than platelet concentrate from buffy coat. Nadiah et al (2013) in their study found that the level of some plasma proteins is reduced after platelet apheresis. Andreu et al (2007) study indicated that leuco-reduced Platelet Rich Plasma Concentrate (PRPC) versus leuco-reduced Apheresis Platelet Concentrate (APC) was same in febrile non hemolytic transfusion reactions and bacteria contamination but the incidence of allergic reactions with APC was four times more than PRPC.…”

Section: Discussionmentioning

confidence: 94%

Effect of Preparation and Storage Methods of Platelet Products on Complement Activity

Salah¹,

Sajedianfa²,

Jalali³

2015

Asian J. of Cell Biology

View full text Add to dashboard Cite

Platelet transfusion is considered a vital therapeutic approach for several diseases. However, like other blood products, it can cause transfusion reactions mainly due to various plasma proteins. With regard to provision of platelet products by a variety of methods including random donors and platelet apheresis, the risk of adverse reactions is assumed to be different in products produced by different methods. The aim of this study was to evaluate the difference in the level of C3 and its derivatives (C3a and C3b anaphylatoxins) as a plasma protein causing reactions in random and platelet apheresis methods. The study was conducted on healthy volunteer blood donors referred to Shiraz Blood Transfusion Organization. Platelet products were prepared by the two mentioned methods based on standard operating methods approved by the Iranian Blood Transfusion Organization. The C3 level was evaluated in three time points using immunoturbidimetric test: immediately after processing, one day and three days later. The data were analyzed using SPSS 16 software in terms of student t test and Pearson correlation. The p<0.05 was considered statistically significant. The C3 level was in maximum level in both method of platelet preparation immediately after preparation and was in minimum in the first day. In addition, statistically significant difference was observed between C3 level in each point of measurement: immediately after preparation (p = 00), the first day (p = 00) and on the third day (p = 0.45). A significant correlation was also observed between C3 level and type of platelet storage bag. Our findings show that the method of platelet preparation and storage plays an important role in the level of accumulated C3 in these products. The C3 concentration, the resulting complement activity and accumulation of anaphylatoxin factors was higher in this product. Therefore, further investigation might prove which method of platelet preparation bears a lower risk of reactions related to the injection of this product.

show abstract

Section: Discussionmentioning

confidence: 94%

Effect of Preparation and Storage Methods of Platelet Products on Complement Activity

Salah¹,

Sajedianfa²,

Jalali³

2015

Asian J. of Cell Biology

View full text Add to dashboard Cite

show abstract

“…[ 20 ] Rate of complication varies from 0.89% to 4.8% and fatalities are approximately 0.003%–0.02% or <1 for every 10,000 procedures. [ 9 ] Common adverse effects in plateletpheresis donors are hypocalcemia, vasovagal attack, and hematoma. [ 21 ] The most common is hypocalcemia due to citrate anticoagulation.…”

Section: Discussionmentioning

confidence: 99%

“…[ 8 ] Different types of cell separators which work on the principle of centrifugation are used for plateletpheresis. [ 5 9 ] The latest-generation apheresis machines have undergone several technical advancements and shown significant progress with respect to collection efficiency, platelet quality, and donor safety. [ 10 ] Some of the machines being used worldwide are Haemonetics ® MCS ® Plus (Haemonetics Corp, Braintee, MA, USA), COBE ® Spectra (Caridian BCT, Lakewood CO), Fresenius AS 104 (Fresenius Medical Care, Walnut Creek, CA, USA), Baxter/Fenwal Amicus (Baxter Healthcare Corp, Deerfield, IL, USA), and Trima Accel ® (Caridian BCT, Lakewood, CO).…”

Section: Introductionmentioning

confidence: 99%

Comparative assessment of single-donor plateletpheresis by Haemonetics^® MCS^® plus and Trima Accel^®

Baruah

Bajpai

2020

Asian J Transfus Sci

View full text Add to dashboard Cite

BACKGROUND: Single-donor platelets (SDPs) prepared by sophisticated automated equipment offer several advantages over random-donor platelets and are being increasingly used to support thrombocytopenic patients. Different apheresis machines working on the principle of centrifugation are being used worldwide to collect platelets. This retrospective study was done to compare plateletpheresis on two automated cell seperators – Haemonetics ® MCS ® Plus and Trima Accel ® . MATERIALS AND METHODS: Data for 100 single-donor plateletpheresis procedures, fifty on each machine, were retrospectively collected and analyzed. Donor characteristics were analyzed by Student's t -test and no significant difference was found between the two groups. The parameters compared between the two machines were yield, collection efficiency, blood volume processed, procedure time, acid-citrate-dextrose (ACD) used, leukodepletion achieved, quality control of the products, and adverse donor reactions. RESULTS: Platelet yield (3.054 ± 0.14 vs. 3.120 ± 0.25), quality control of the platelets, leukodepletion achieved, and donor safety were comparable in both the machines. The blood volume processed (2230.74 ± 227.01 vs. 2452.90 ± 318.61), ACD used during procedure (265.48 ± 43.21 vs. 298.10 ± 53.32), procedural time (55.92 ± 13.00 vs. 68.86 ± 12.64), and the postprocedural decrease in donor count in Trima Accel ® (183.10 ± 23.99 vs. 161.44 ± 63.47) were significantly less than those in Haemonetics ® MCS ® Plus. The median collection efficiency of Trima Accel ® was found to be greater than Haemonetics ® MCS ® Plus (0.000649 vs. 0.000608, P = 0.020). CONCLUSION: Both Trima Accel ® and Haemonetics ® MCS ® Plus can collect SDPs safely and efficiently. Trima Accel ® has higher collection efficiency and reduced incidence of citrate-related adverse effects. It also has better potential to optimize productivity due to decreased procedural time.

show abstract

“…Plateletpheresis has effects on coagulation parameters by decreasing pro-thrombotic FVIII, fibrinogen, anti-thrombin, protein C and protein S levels, albeit maintaining them within acceptable ranges [50, 51]. While von-Willebrand multimeric structures remain unchanged, von Willebrand levels can drop by up to 15% as a result of dilution and replacement of plasma by anticoagulant during apheresis [52].…”

Section: Discussionmentioning

confidence: 99%

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

et al. 2017

View full text Add to dashboard Cite

Extreme thrombocytosis induces an acquired thrombotic-hemorrhagic diathesis, and left uncontrolled is a harbinger of potentially fatal vascular complications. Currently, cytoreduction with medical therapy remains the mainstay of hyperthrombocytosis management. However, it offers a less-than-ideal option in situations where a rapid reduction in platelets is urgently needed, as in the presence of vital end-organ ischemia or to ameliorate of life-threatening hemorrhage. The role of thrombocytapheresis, or plateletpheresis, in hyperthrombocytosis has become increasingly obsolete given the proactive titration of cytoreductive therapies and early identification and correction of reversible causes of reactive thrombocytosis. Despite its narrowed indications, plateletpheresis continues to offer a valuable temporizing measure in platelet count reduction before cytoreductive agents exert their maximal effect. In this context, it is important for the treating physician to be aware of the symptoms and risks associated with hyperthrombocytosis to inform best clinical practices. In this review, we discuss the role of plateletpheresis in the modern-day management of hyperthrombocytosis in patients with myeloproliferative neoplasms through a case based review of the literature. It becomes apparent throughout the discussion that the decision to perform plateletpheresis should be individualized based upon the clinical scenario, degree of thrombocytosis, available infrastructure and every patient’s risk profile.

show abstract

Effects of plateletpheresis on blood coagulation parameters in healthy donors at National Blood Centre, Kuala Lumpur, Malaysia

Cited by 16 publications

References 24 publications

Effect of Preparation and Storage Methods of Platelet Products on Complement Activity

Effect of Preparation and Storage Methods of Platelet Products on Complement Activity

Comparative assessment of single-donor plateletpheresis by Haemonetics^® MCS^® plus and Trima Accel^®

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

Contact Info

Product

Resources

About

Effects of plateletpheresis on blood coagulation parameters in healthy donors at National Blood Centre, Kuala Lumpur, Malaysia

Cited by 16 publications

References 24 publications

Effect of Preparation and Storage Methods of Platelet Products on Complement Activity

Effect of Preparation and Storage Methods of Platelet Products on Complement Activity

Comparative assessment of single-donor plateletpheresis by Haemonetics® MCS® plus and Trima Accel®

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

Contact Info

Product

Resources

About

Comparative assessment of single-donor plateletpheresis by Haemonetics^® MCS^® plus and Trima Accel^®